Wisdom Launches New Short-form Audio Format ‘Voice Answers’ in Bid to Solve Social Audio’s Biggest Challenge
Wisdom, a social audio app that facilitates one-to-one meaningful conversations, today launches a pioneering new format, ‘Voice Answers’, an asynchronous short-form audio take on the traditional questions and answers format.
Voice Answers was designed to overcome the limitations associated with the live social audio format, popularised by Clubhouse. Now the centerpiece of the app, ‘Voice Answers’ delivers an algorithmically curated feed of wise answers to self-discovery questions like “Describe your idea of a perfect day.” to mentoring questions like “How do I break into the film industry?” to life hack questions like “How do I set boundaries in a relationship?”
Social Audio has demonstrated tremendous promise, with platforms like Clubhouse, Spotify, Twitter, Discord and LinkedIn rolling out social audio experiences to hundreds of millions of users. However, social audio has recently been much maligned, with recent headlines including “Is social audio already dead?” and “The Rise And Fall Of Social Audio.”
Dayo Akinrinade founder and CEO of Wisdom comments: “The biggest challenge with social audio today is its low listening value-to-word ratio. While podcasts are carefully planned and produced, social audio tends to be more freewheeling and, as a result, the content quality is less reliable. Another challenge is the consumption of live audio content being limited to whomever happens to be listening at a given time. Inspired by TikTok’s content-first algorithm and short-video format, my goal with Voice Answers' asynchronous short-form audio format, is to bring elements of TikTok’s innovation to social audio by preserving the excitement of live conversations, whilst also solving the low listening value-to-word ratio problem that's endemic to the live social audio format that Clubhouse pioneered.”
With today’s launch of Voice Answers, the Wisdom app opens to a voice answer, which the user can listen to or swipe. Each swipe informs the machine-learning algorithm, helping improve content recommendations to provide a stream of personalised, high-quality answers.
To be creator-friendly, Voice Answers are restricted to less than 60 seconds and Wisdom auto-generates an audiogram for each Voice Answer, which creators can easily share on other social networks.
Dayo continues: “Questions and answers are powerful tools to unlock insights and gain a deeper understanding of who we are and the world around us. Early in my career, as a black woman in tech, I lacked access to wise people, which hampered my progression. The Voice Answers format is positioned to empower us to share our wisdom with the world, whilst simultaneously pioneering a new short form asynchronous audio format which I hope will overcome the current challenges associated with social audio.”
Download Wisdom for Android on Google Play store here
Download Wisdom for iOS on Apple App Store here
—---- END PRESS RELEASE —--
Notes to the Editor
A selection of supporting hi-res feature images can be found on Google Drive here
About Wisdom
Wisdom is a venture-backed social audio app on a mission to leave the world a bit wiser than we found it. Wisdom connects you for live one-to-one conversations and Q&A, centered on knowledge-sharing and self-discovery. Within a year of launch, Wisdom was awarded Apple’s App Store ‘App of the Day’ twice and TechRadar’s ‘Best Android Apps of 2022’.
Wisdom is a pioneer in the social audio space having created ‘Voice Answers’ an asynchronous, short-form audio take on the traditional Q&A format, which delivers an algorithmically curated feed of high-quality voice answers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005094/en/
Contact information
Danielle Zhu or Sarah Herrera from Thinking Hat PR:
danielle@thinkinghatpr.com
sarahh@thinkinghatpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 15:00:00 EET | Press release
Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evaluated as presenting the true 'Gold Standard' in regenerative medicine by perfectly resolving the inherent challenges—such as immune rejection, incomplete reprogramming, and the inheritance of aging—that have been cited as limitations of existing stem cell therapies. Clonell's SCNT technology establishes a patient-specific embryonic stem cell line by transferring the nucleus of a patient's somatic cell into a healthy enucleated oocyte. This process
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi ® /Minjuvi ® ) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 14:30:00 EET | Press release
Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years of age, or age-adjusted IPI (aaIPI) of two to three (2-3) for patients ≤60 years of age. The trial met its primary endpoint of progression-free survival (PFS) by investigator assessment (Hazard Ratio 0.75 [0.59,0.96]; p-value 0.019), according to Lugano 2014 criteria. The trial also met its key secondary endpoint of event-free survival (EFS) by investigator assessment. No new safety signals were observed. “The frontMIND stud
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 14:30:00 EET | Press release
Cybin Inc. (the “Company”) doing business as Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (“Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing NSAs, today announced that the Company will operate under the business name Helus Pharma (pronounced “Heal-Us”) and trade on Nasdaq with ticker symbol HELP. “Our new business name more accurately describes our compounds and reflects our anticipated transformation from a global clinical stage discovery and development company to a commercial-ready pharmaceutical company, with our two lead candidates HLP003 and HLP004,” said Eric So, interim chief executive officer of the Company. “Over the past several years, we have advanced our pipeline portfolio of differentiated, proprietary NSA drug candidates, which includes over 350 filed patents with more than 100 already granted. We are approaching the commercialization of HLP003 with strong clinical data and significant market potential, subject to the
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 14:00:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell production to control hematocrit levels in patients with PV. “This is an important milestone toward our goal of addressing critical gaps that patients living with polycythemia vera face today,” said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. “The comprehensive VERIFY study data underscore rusfertide’s strong clinical profile and potential to provide sustained hematocrit control while reducing phlebotomy and symptom burden. Our collaboration with Protagonist exemplifies how partnerships can advance innovative science, with a focus on m
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance with a Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 14:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
